LENZ Therapeutics (LENZ) Liabilities and Shareholders Equity (2020 - 2026)

LENZ Therapeutics (LENZ) has 7 years of Liabilities and Shareholders Equity data on file, last reported at $272.5 million in Q1 2026.

• Quarterly Liabilities and Shareholders Equity rose 35.42% year-over-year to $272.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 billion (up 19.36% YoY) and the FY2025 annual result came in at $305.9 million, up 42.07% from the prior year.
• Liabilities and Shareholders Equity retreated to $272.5 million in Q1 2026 per LENZ's latest filing, from $305.9 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $378.6 million in Q1 2022 and bottomed at $70.4 million in Q4 2023.
• The 5-year median for Liabilities and Shareholders Equity is $266.2 million (2023), against an average of $258.2 million.
• The widest annual swing landed in 2023, when Liabilities and Shareholders Equity sank 78.14%; it then surged 205.93% in 2024.
• Tracing LENZ's Liabilities and Shareholders Equity over 5 years: stood at $321.9 million in 2022, then slumped by 78.14% to $70.4 million in 2023, then surged by 205.93% to $215.3 million in 2024, then soared by 42.07% to $305.9 million in 2025, then dropped by 10.9% to $272.5 million in 2026.
• Per Business Quant, the three latest LENZ Liabilities and Shareholders Equity figures stand at $272.5 million (Q1 2026), $305.9 million (Q4 2025), and $210.7 million (Q3 2025).

Peer Comparison